Research programme: bacteriophage therapeutics - AmpliPhi Biosciences

Drug Profile

Research programme: bacteriophage therapeutics - AmpliPhi Biosciences

Alternative Names: AmpliPhage-001; BioPhage-PR; BioPhage-SM

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocontrol
  • Developer AmpliPhi Biosciences Corporation; Frenchay Hospital; University of Bath
  • Class Bacteriophages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Burn infections; Pseudomonal infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pseudomonal-infections in United Kingdom (Inhalation, Aerosol)
  • 04 Nov 2017 No recent reports of development identified for research development in Burn-infections in United Kingdom (Topical, Gel)
  • 04 Aug 2016 AmpliPhi Biosciences Corporation has patent protection for bacteriophage-based therapeutics in the Japan and Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top